Ionis Pharma announced a Phase 2b study conducted by Pfizer and evaluating vupanorsen (formerly IONIS-ANGPTL3-LRx) for patients with elevated non-HDL-C and triglycerides has met its primary endpoint. Patients treated with vupanorsen achieved a statistically significant reduction in non-HDL-C at all doses tested at 24 weeks compared to placebo, meeting the primary endpoint. Key secondary endpoints were also reached, with statistically significant reductions in triglycerides (TG) and ANGPTL3 observed at all vupanorsen dose levels at 24 weeks compared to placebo.
In November 2019, Pfizer licensed vupanorsen from Akcea in a worldwide exclusive agreement.
The global multicenter, double-blind, placebo-controlled, dose-ranging study TaRgeting ANGPTL3 with an aNtiSense oLigonucleotide in AdulTs with dyslipidEmia (TRANSLATE-TIMI 70) enrolled 286 patients (≥ 40 years old) with dyslipidemia, defined in this study as participants with elevated non-HDL-C (≥ 100 mg/dL) and TG (150-500 mg/dL), who are receiving a stable dose of a statin. Participants received either 80 mg, 120 mg or 160 mg every 4 weeks, or 60 mg, 80 mg, 120 mg or 160 mg every two weeks via subcutaneous injection.
Quality journalism costs money to produce. We will be reinvesting the proceeds of these subscriptions into an increasing volume of high quality, independent, unbiased reporting and expert analysis. Our subscription tiers use the ‘honor system’ – please do not abuse it. All tiers of service provide the same level of access to content. We are grateful for all of you, and we hope you reciprocate.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).